Currently we test and support the following browsers:
St. Jude investigators have shown that when the cancer drug irinotecan is given in low doses for multiple days, it eliminates the need to perform costly genetic testing that would delay treatment.
St. Jude researchers have found evidence in a mouse model that simultaneous therapy with a drug that regulates movement of topotecan from the bloodstream can reduce its concentration in the cerebrospinal fluid (CSF).
The best dose of a chemotherapy drug for one child is not necessarily the best dose for another. St. Jude scientists are simplifying individualized therapy for children with cancer.
A team of researchers at St. Jude has figured out how to minimize the number of times children receiving the cancer drug topotecan must have blood samples drawn when performing pharmacokinetic studies, while ensuring accurate results.
Monitoring and fine tuning the levels of the cancer drug topotecan in children with neuroblastoma holds promise for maximizing the drug's effectiveness while reducing its toxicity.